DeepMed Research

Center for Research in Security Prices, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Effectiveness of Interventions to Teach Respiratory Inhaler Technique (E-TRaIN)

Not Applicable

Completed

Conditions: Asthma
Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Behavioral: Brief Intervention
Behavioral: Teach-To-Goal

First Posted Date: 2011-08-31

Last Posted Date: 2019-11-19

Lead Sponsor: University of Chicago

Target Recruit Count: 120

Registration Number: NCT01426581

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy

Recruiting

Conditions: Gastric Cancers

First Posted Date: 2011-08-15

Last Posted Date: 2024-07-31

Lead Sponsor: University of Chicago

Target Recruit Count: 1000

Registration Number: NCT01416714

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

Impact of Exenatide on Sleep Duration

Completed

Conditions: Type 2 Diabetes

First Posted Date: 2011-08-15

Last Posted Date: 2023-04-26

Lead Sponsor: University of Chicago

Target Recruit Count: 8

Registration Number: NCT01416649

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions

Phase 2

Completed

Conditions: Precancerous Condition
Lip and Oral Cavity Squamous Cell Carcinoma
Oral Cavity Verrucous Carcinoma

Interventions: Other: placebo
Drug: vandetanib
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Procedure: biopsy
Other: pharmacological study

First Posted Date: 2011-08-11

Last Posted Date: 2021-01-14

Lead Sponsor: University of Chicago

Target Recruit Count: 20

Registration Number: NCT01414426

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis

Phase 4

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Alemtuzumab

First Posted Date: 2011-07-15

Last Posted Date: 2018-12-07

Lead Sponsor: University of Chicago

Target Recruit Count: 8

Registration Number: NCT01395316

Cord Blood Transplantation for Patients With Cancer

Phase 2

Terminated

Conditions: Hematological Disease

Interventions: Drug: Melphalan
Drug: Antithymocyte Globulin (ATG)
Drug: Fludarabine
Drug: Busulfan
Drug: Total Body Irradiation (TBI)

First Posted Date: 2011-05-24

Last Posted Date: 2015-04-30

Lead Sponsor: University of Chicago

Target Recruit Count: 1

Registration Number: NCT01359254

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Feasibility of Imaging in the Treatment of Patients With Advanced Head and Neck Cancer

Early Phase 1

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: 99mTc-EC-DG

First Posted Date: 2011-05-24

Last Posted Date: 2020-05-08

Lead Sponsor: University of Chicago

Target Recruit Count: 12

Registration Number: NCT01359267

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Study of Stereotactic Body Radiation Therapy in Patients With Intact Pancreatic Cancer

Phase 1

Conditions: Pancreatic Cancer

Interventions: Radiation: Stereotactic Radiation

First Posted Date: 2011-04-27

Last Posted Date: 2021-04-01

Lead Sponsor: University of Chicago

Target Recruit Count: 17

Registration Number: NCT01342354

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer

Not Applicable

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Bicalutamide
Drug: Dutasteride
Drug: Finasteride
Radiation: Radiation

First Posted Date: 2011-04-27

Last Posted Date: 2024-05-24

Lead Sponsor: University of Chicago

Target Recruit Count: 74

Registration Number: NCT01342367

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Comparison of Two Lidocaine Administration Techniques

Phase 4

Completed

Conditions: Pain

Interventions: Drug: lidocaine

First Posted Date: 2011-04-06

Last Posted Date: 2018-07-26

Lead Sponsor: University of Chicago

Target Recruit Count: 481

Registration Number: NCT01330134

Locations: 🇺🇸
The University of Chicago Medical Center, Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy